At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 23 enrolled
Drug / intervention
Ibrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Optimizing Post-allogeneic Hematopoietic Cell Transplant Outcomes for Lymphoma Using Ibrutinib
In Brief
A Phase 2 clinical trial evaluating Ibrutinib and Laboratory Biomarker Analysis for Blastoid Variant Mantle Cell Lymphoma and 8 related conditions. Completed, enrolled 23 participants across 5 sites.
Detailed Summary
This phase II trial studies how well ibrutinib works in treating patients after a donor stem cell transplant for lymphoma that is not responding to treatment or has come back. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBlastoid Variant Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Follicular Lymphoma, Refractory Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartNov 2016
Primary CompletionNov 2021
Study CompletionOct 2023
TodayJul 2026
First PostedAug 17, 2016
Enrollment StartNov 1, 2016
Primary CompletionNov 18, 2021
Study CompletionOct 1, 2023
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 9.9 years ago
Interventions
Ibrutinibdrug
Given by mouth
Laboratory Biomarker Analysisother
Correlative studies